Soluble interleukin-2 receptor [sIL-2R] as a tumor marker in hematologic malignancies

This work aimed to evaluate serum levels of sIL-2R in some of the hematologic malignancies and to find out if it could be a predictive marker of tumor burden and response to therapy. The mean value of sIL-2R in patients with acute lymphoblastic leukemia [ALL] was significantly higher than the controls. It was also significantly high in the patients with activity as compared with those at remission. Patients with chronic lymphocytic leukemia [CLL] had significantly elevated sIL-2R compared with the controls. The mean value of sIL-2R in the newly diagnosed cases of CLL was significantly higher than that of the group under treatment. There was no significant difference in the mean value of sIL-2R on comparing patients with stage I CLL to those with stage II. There was a significant difference between patients with stage I CLL and those with stage IV and between patients with stage II and stage IV. Newly diagnosed cases had a significantly high mean serum value of sIL-2R compared with those under treatment. Also, patients under treatment showed a significantly high mean serum value of sIL-2R compared with those at remission. Thus, it is clear that measurements of serum sIL-2R in patients with ALL, CLL, non-Hodgkin's lymphoma [NHL] and Hodgkin's lymphoma [HL] could offer a useful marker for tumor burden, prognosis and monitoring of treatment

Clinical relevance of apo-1 / fas and Bcl-2 expression in childhood acute lymphoblastic leukemia

This study tried to speculate the role of Apo-I antigen and BCL-2 oncoprotein in newly diagnosed children with acute lymphoblastic leukemia [ALL] and to find out if they have any possible role as predictors of the outcome and response to therapy. Before induction therapy Fas antigen expression had a significantly low mean value in the patients with failed induction compared with patients with complete remission. Patients with failed induction showed a significantly higher pre-induction value of patients who showed complete remission. No significant correlation was found between the percentage of Fas expression among patients with ALL was variable. In spite of having high values of Bcl-2, yet, neither Fas antigen expression nor the level of BCL-2 oncoprotein could be considered as a sensitive predictor of the outcome and response to therapy

Soluble interleukin-2 receptor [sIL-2R] in some hematologic malignancies

The aim of this study was to evaluate serum levels of sIL-2R in some of the hematologic malignancies and to find out if it could be a predictive marker of tumor burden and response to therapy. The mean value of sIL-2R in ALL was significantly elevated than in the controls. It was also significantly high in the patients with activity as compared with those at remission. Also, the mean value of sIL-2R in NHL was significantly elevated compared with the controls. Newly diagnosed cases had a high mean serum value of sIL-2R compared with those under treatment and a more significant elevation in comparison with the cases at remission. Also, patients under treatment showed a significantly higher mean serum value of sIL-2R than patients at remission. In patients with HL the mean value of sIL-2R was significantly elevated as compared with the controls. Newly diagnosed cases with HL had a significantly high mean serum value of sIL-2R as compared with patients under treatment and at remission. Also, patients under treatment showed a significantly high mean serum value of sIL-2R compared with those at remission